Analysts

The reopening of the Strait of Hormuz is expected to alleviate immediate threats to global energy supplies, but analysts caution that the economic repercussions from the recent conflict will persist for months, maintaining inflationary pressures across various economies.

Zealand Pharma's stock has faced significant declines following disappointing data on its weight loss drug survodutide, leading analysts to reduce sales forecasts and shift focus to its other drug, petrelintide, which may offer better prospects in the obesity market.

The stock market is rebounding from recent losses, with notable movements in the AI chip sector and Amazon's plans to monetize its custom chips, which could impact competition in the semiconductor market.

Arete Research has set a bullish price target of $401 for SpaceX shares by the end of 2027, suggesting a potential doubling from their current price, driven by advancements in rocket reusability and the growth of its Starlink satellite service. This optimistic outlook contrasts with more conservative targets from other firms, highlighting the uncertainty surrounding SpaceX's future performance.

Nvidia is poised to benefit from a shift in capital expenditures towards chips, particularly GPUs, as demand for AI technology continues to grow, potentially increasing its market share and revenue significantly by 2030.

The recent comments from President Trump regarding a potential partnership between Apple and Intel have significantly boosted Intel's stock, highlighting the company's pivotal role in the U.S. semiconductor industry and its ongoing turnaround efforts.